secwatch.observer — SEC 8-K summary
======================================

Issuer:     bluebird bio, Inc. (—)
CIK:        0001293971
Form:       8-K
Filed at:   2024-05-29T23:59:59+00:00
Accession:  0001193125-24-148602
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

bluebird bio CFO Christopher Krawtschuk departs June 10; O. James Sterling appointed as CFO
--------------------------------------------------------------------------------

- CFO Christopher Krawtschuk to depart June 10, 2024, not due to any disagreement with the company on accounting policies or strategy.
- O. James Sterling, formerly CFO of Renalytix plc, appointed as CFO and principal accounting officer effective June 10, 2024.
- Sterling's compensation: $500k base salary, $100k sign-on bonus, 45% target bonus, and initial equity grant of 300k options, 100k RSUs, and 50k PRSUs (subject to shareholder approval).
- Severance upon termination without cause or for good reason includes one times base salary (or one times base plus target bonus within 12 months of Change in Control) plus COBRA subsidy for 12 months.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1293971/000119312524148602/0001193125-24-148602-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1293971/000119312524148602/d796778d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-148602

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer